Veru Inc. (VERU)
NASDAQ: VERU · Real-Time Price · USD
0.3731
+0.0076 (2.08%)
At close: Aug 7, 2025, 4:00 PM
0.3728
-0.0003 (-0.08%)
Pre-market: Aug 8, 2025, 5:37 AM EDT
Satixfy Communications Revenue
Veru Inc. had revenue of $16.89M in the twelve months ending March 31, 2025, up 134.43% year-over-year. In the fiscal year ending September 30, 2024, Veru Inc. had annual revenue of $16.89M with 3.62% growth.
Revenue (ttm)
$16.89M
Revenue Growth
+134.43%
P/S Ratio
3.23
Revenue / Employee
$80,412
Employees
210
Market Cap
54.69M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 16.89M | 589.46K | 3.62% |
| Sep 30, 2023 | 16.30M | -23.06M | -58.59% |
| Sep 30, 2022 | 39.35M | -21.91M | -35.76% |
| Sep 30, 2021 | 61.26M | 18.67M | 43.83% |
| Sep 30, 2020 | 42.59M | 10.79M | 33.92% |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
VERU News
- 1 day ago - Veru Announces Reverse Stock Split - GlobeNewsWire
- 16 days ago - Veru to Participate in the 2025 BTIG Virtual Biotech Conference - GlobeNewsWire
- 2 months ago - Veru to Participate in the Virtual BTIG Obesity Health Forum - GlobeNewsWire
- 2 months ago - Veru's Enobosarm Shows Muscle In Wegovy Combo Trial - Benzinga
- 2 months ago - Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone - GlobeNewsWire
- 2 months ago - Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom - Seeking Alpha
- 3 months ago - Veru Inc. (VERU) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level - Accesswire